Prestige Brands Holdings, Inc. — FY2013 Form 10-K
Reporting period: Fiscal year ended March 31, 2013. The filing is for FY2013, not a standalone 2012 Q4 report; it includes quarterly data for fiscal Q4 ended March 31, 2013. The registrant name in the filing is Prestige Brands Holdings, Inc.
Business context
The company markets over-the-counter healthcare and household cleaning products, primarily in North America, using an asset-light model that outsources manufacturing and distribution. FY2013 included the first full year of most brands acquired from GlaxoSmithKline (GSK) in 2012. The company sold the Phazyme brand in October 2012 and used the proceeds to repay debt.
Key financial results
| Metric | FY2013 | FY2012 |
|---|---|---|
| Total revenue | $623.6 million | $441.1 million |
| Gross profit / margin | $347.2 million / 55.7% | $227.4 million / 51.6% |
| Operating income | $191.9 million | $102.8 million |
| Net income | $65.5 million | $37.2 million |
| Diluted EPS | $1.27 | $0.73 |
| Cash from operating activities | $137.6 million | $67.5 million |
| Capital expenditures | $10.3 million | $0.6 million |
| Cash and cash equivalents at year-end | $15.7 million | $19.0 million |
| Debt principal at year-end | $978.0 million | $1,135.0 million |
Operating cash flow less capital expenditures was approximately $127.3 million in FY2013. The current ratio was approximately 1.7, based on current assets of $164.2 million and current liabilities of $96.7 million.
Material changes versus prior year
- Revenue increased 41.4%, primarily due to the acquired GSK brands, which contributed $211.2 million of FY2013 revenue. OTC Healthcare revenue rose 55.6% to $536.9 million; Household Cleaning revenue fell 9.8% to $86.7 million.
- Gross margin improved, chiefly from the greater share of higher-margin OTC Healthcare sales and the GSK portfolio. Advertising and promotion rose to $90.6 million from $57.1 million.
- Net interest expense increased to $84.4 million from $41.3 million, reflecting higher average borrowings and accelerated amortization of financing costs and debt discount. The effective tax rate was 38.2%, compared with 39.2%.
- Operating cash flow increased by $70.2 million, reflecting higher profitability and working-capital changes. The company repaid $190.0 million of term debt; year-end debt declined by $157.0 million.
Outlook, risks and unusual items
- No numerical revenue or earnings guidance is provided. Management expects international revenue to continue growing and anticipates compliance with debt covenants in the ensuing year; these are expectations, not formal financial guidance.
- At March 31, 2013, the company had $42.0 million of unused capacity under its $75.0 million asset-based revolver and was in compliance with applicable covenants. It reported no quarterly term-loan principal payments due before maturity following voluntary repayments. Total debt remains substantial, with significant interest obligations and restrictive covenants.
- Variable-rate term and revolver debt totaled $478.0 million. Management estimated that a one-percentage-point increase in rates would reduce annual pretax earnings and cash flow by approximately $4.6 million, holding other factors constant.
- The GSK acquisition materially changed the company’s scale and financing. FY2013 also included a $1.4 million debt-extinguishment loss from the February 2013 term-loan refinancing. The Phazyme sale generated $22.3 million in proceeds with no significant gain or loss. No goodwill or intangible impairment was recorded.
- Key risks include competition and private-label products, dependence on Walmart and other major customers, reliance on third-party manufacturers and a single primary distribution center, product recalls and regulation, input-cost inflation, and the large concentration of assets in goodwill and intangibles. Some Household Cleaning brands had declining revenue; two reporting units had fair values less than 10% above carrying values.
- The company disclosed routine legal matters and stated that their resolution, considering recorded reserves, was not expected to have a material adverse effect. It also noted several recent product recalls but did not provide details in the supplied filing text.
- FY2013 Q4 revenue was $154.5 million, net income was $19.3 million, and diluted EPS was $0.37. The comparable FY2012 Q4 reported a $15,000 net loss.
Important facts for investors to verify
- How much of revenue and profit growth is recurring organic growth versus acquired-brand contribution, and whether Household Cleaning declines continue.
- Debt repayment capacity, variable-rate exposure, covenant headroom, and the assumptions behind estimated future interest payments.
- Performance of the acquired GSK brands after transition services ended, including required advertising, integration costs, and realized returns.
- Whether declining brands or changes in valuation assumptions could trigger goodwill or intangible-asset impairment; these assets totaled approximately $1.54 billion.
- Exposure to Walmart, which accounted for 15.9% of FY2013 gross revenue, and to third-party suppliers, retailers, and the St. Louis distribution center.
- Product recall details and any material developments in litigation or regulatory matters; the filing text does not provide a clear itemized account of recent recalls.